» Orexigen(R) Therapeutics Announces Completion Of Patient Enrollment In Phase III Clinical Program For Contrave(R)
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-303…